Le Lézard
Classified in: Health, Business
Subject: RCN

Sangamo Therapeutics Announces Technology Leadership Changes

RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the Company effective July 20th to pursue an opportunity with a startup biotech company. Edward Rebar, Ph.D., has been named Senior Vice President and Chief Technology Officer, effective immediately.

Sangamo Therapeutics, Inc. (PRNewsfoto/Sangamo Therapeutics, Inc.)

"We wish Michael well in his new endeavor," said Sandy Macrae, CEO of Sangamo. "We are grateful for his contributions to Sangamo over the years and are excited for him as he pursues this ground-floor opportunity at a biotech startup."

Dr. Holmes joined Sangamo in 2001 as a senior scientist and over the years has been promoted to lead many of Sangamo's research programs. Along with Dr. Rebar and other Sangamo scientists, Dr. Holmes made important contributions to the development of zinc finger proteins for therapeutic, research and agricultural applications. He was named Chief Technology Officer earlier in 2018.

Dr. Rebar joined Sangamo in 1998, and over the last 20 years he has led the development of the Company's zinc finger protein platform. He has authored over 60 publications relating to the development of customized DNA binding proteins and nucleases for genome editing.  Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley.  Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.

"I'm very pleased to announce Ed Rebar's promotion to Chief Technology Officer," Macrae said. "During his tenure at Sangamo, Ed has led the development and optimization of our core zinc finger technology. In the field of genome editing he is recognized as a leader and a strong voice for setting very high standards for editing technology being developed for therapeutic use."

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit the Company's website at www.sangamo.com.


SOURCE Sangamo Therapeutics, Inc.

These press releases may also interest you

at 09:02
The SIFMA Foundation and Newday Investing today announced a collaboration to add a new component to  SIFMA Foundation's acclaimed Stock Market Gametm program that will focus on sustainable investing. The enhancement, a first in the history of the...

at 09:00
A5, a full-service System Implementation and Digital Transformation expert, announced today it has completed the acquisition of Ramsey Solutions, a Salesforce technology consulting company that implements solutions to help businesses improve their...

at 09:00
Talent Inc., the global leader in career services, announced today the acquisition of the assets of eDirect Publishing Inc. and their ResumeRabbit product, a service that instantly posts a job seeker's resume to dozens of job boards using a single...

at 09:00
Verve, the leading mobile platform for location-powered programmatic video and display marketing, today announces its exclusive partnership with Accretive Media, a programmatic digital out-of-home (DOOH) advertising platform. The partnership brings...

at 09:00
Wamberg Genomic Advisors and National Benefit Partners (NBP) have partnered to distribute Wamberg's Cancer Guardiantm program as an employee benefit to leading employers nationwide. Cancer Guardian is a leading advancement in personalizing cancer...

at 09:00
CAS, a division of the American Chemical Society, partnered with iChemLabs to optimize the efficiency of chemical structure drawing in SciFinder-n®, especially in touch devices, using ChemDoodle®. Built on the trusted chemical research collection...

News published on 13 july 2018 at 16:15 and distributed by: